ISPE, through its members’ expertise in epidemiologic research, can provide guidance and drive innovative solutions to key RWE issues.
COVID-19 Work
View the dedicated webpage featuring ISPE members’ work aimed at addressing the COVID-19 pandemic.
Join us for ICPE All Access and celebrate 35 years of real-world science. Our lineup of expert presenters will bring you the latest developments, insights, and trends for pharmacoepidemiology and therapeutic risk management.
ICPE All Access is a collaborative, vibrant platform for sharing stories and ideas with your peers from around the world.
With so many factors related to the COVID-19 pandemic still unknown, and considering the health and safety of our attendees, the International Society for Pharmacoepidemiology (ISPE) has made the difficult decision to cancel the 36th ICPE Meeting in Berlin, Germany. View the full update here.
The most recent retractions of two high-profile COVID-19 studies have reemphasized the volatility of the public and scientific acceptance of evidence from real-world data and the use of observational designs to make causal inferences about drug effects. Click here to view the full update.
The protests in the US and other countries in response to George Floyd’s death have again emphasized the longstanding and deeply rooted racism and injustice that ISPE members may face. Globally increasing trends of populism, separatism, and fascism and disregard of science are the broader issues that threaten social equality and public health, including our ability to control COVID-19.
The International Society for Pharmacoepidemiology condemns racism and any other form of discrimination against social groups. Each of us individually and as members of ISPE, a society devoted to improving public health needs to confront these threats with all our abilities. We invite suggestions to info@pharmacoepi.org on how we can advance our reach as an international society to support racial justice, equity, and the firm integration of science in decision-making.
To ensure transparency and continuous engagement with ISPE members, the task force is planning to issue regular progress newsletters to ISPE members. Each newsletter will highlight the objectives and work of a subgroup. Our inaugural newsletter highlights the RWE Reproducibility and Transparency and Collaboration with ISPOR subgroup.
ISPE has launched the RWE Task Force to have a formal entity within ISPE to promote the scientific methods, education, and policies related to the development, use, and interpretation of Real-World Data and Real-World Evidence.
I am pleased to announce that Wei Zhou and Helga Gardarsdottir have graciously agreed to co-chair this new task force. Together with the ISPE executive committee and considering many members’ suggestions, we have identified 11 subgroups that will tackle either specific tasks or liaise with other scientific or clinical communities to promote pharmacoepidemiologic methods in the RWE world. Wei and Helga will reach out early next year with more detail on these subgroups, their chairs and a call for participation. Please click here to view the full update.
Roadmap of the Pathways for Combination Medical Products
Presented by Veronica Sansing-Foster, PhD, MS and Patricia M. Giordano, DO
Tuesday, August 4, 2020
10:00 - 11:00am ET
Register Today
Interested in presenting a webinar? Submit a webinar proposal here
